DB959

	Lead Identification	Candidate Selection Proof of Principle	Pre-Clinical Development	Phase 1	Phase 2a
Development Phase

Product/Technology Name: DB959

Condition/Disease Targeted: Type 2 Diabetes

Product Development: The DB959 regulates certain nuclear receptors (peroxisone proliferator-activated receptors, PPARs) that regulate the genes involved in controlling blood sugar levels and certain lipids (e.g. total cholesterol, HDL-cholesterol, triglycerides). The compound acts as an agonist of PPAR delta and PPAR gamma. The Company has completed all IND-enabling toxicology studies and plans to submit an IND in 4Q08 and initiate clinical trials in 1Q09.